Panitumumab in Japanese patients with unresectable colorectal cancer

a post-marketing surveillance study of 3085 patients.

Narikazu Boku, Kenichi Sugihara, Yuukou Kitagawa, Kiyohiko Hatake, Akihiko Gemma, Naoya Yamazaki, Kei Muro, Tetsuya Hamaguchi, Takayuki Yoshino, Ikuo Yana, Hiroshi Ueno, Atsushi Ohtsu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Panitumumab was approved in Japan in April 2010 for the treatment of Kirsten rat sarcoma-2 virus oncogene wild-type unresectable and recurrent colorectal cancer. We conducted a post-marketing surveillance study to evaluate the safety and effectiveness of panitumumab. After panitumumab was commercially available in Japan, all patients to be treated with panitumumab were enrolled. Data on baseline characteristics, treatment outcome, and incidence and severity of adverse drug reactions were collected. In total, 3091 patients were registered. In the safety analysis set (n = 3085), panitumumab was administered as monotherapy (40.7%) or combination therapy (59.4%). The median treatment duration was 113 days (range: 1-559 days), and 451 (14.6%) patients received panitumumab for ≥10 months. The overall incidence rate of adverse drug reactions was 84.1%, and the most common adverse drug reaction was skin disorders (78.4%). The incidence rates (all grades) of interstitial lung disease, infusion reaction, electrolyte abnormalities and cardiac disorders were 1.3% (mortality rate: 0.6%), 1.5, 19.3 and 0.2%, respectively. The median survival time of patients treated with panitumumab monotherapy as the third-line, or later, therapy was 10.3 months. This post-marketing survey in clinical practice confirmed the safety and effectiveness of panitumumab. The benefit/risk balance for panitumumab in Japanese patients with unresectable colorectal cancer remains favorable.

Original languageEnglish
Pages (from-to)214-223
Number of pages10
JournalJapanese Journal of Clinical Oncology
Volume44
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Marketing
Colorectal Neoplasms
Drug-Related Side Effects and Adverse Reactions
Safety
Incidence
Japan
panitumumab
Interstitial Lung Diseases
Therapeutics
Oncogenes
Sarcoma
Electrolytes
Viruses
Skin
Survival
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Panitumumab in Japanese patients with unresectable colorectal cancer : a post-marketing surveillance study of 3085 patients. / Boku, Narikazu; Sugihara, Kenichi; Kitagawa, Yuukou; Hatake, Kiyohiko; Gemma, Akihiko; Yamazaki, Naoya; Muro, Kei; Hamaguchi, Tetsuya; Yoshino, Takayuki; Yana, Ikuo; Ueno, Hiroshi; Ohtsu, Atsushi.

In: Japanese Journal of Clinical Oncology, Vol. 44, No. 3, 2014, p. 214-223.

Research output: Contribution to journalArticle

Boku, N, Sugihara, K, Kitagawa, Y, Hatake, K, Gemma, A, Yamazaki, N, Muro, K, Hamaguchi, T, Yoshino, T, Yana, I, Ueno, H & Ohtsu, A 2014, 'Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.', Japanese Journal of Clinical Oncology, vol. 44, no. 3, pp. 214-223. https://doi.org/10.1093/jjco/hyt196
Boku, Narikazu ; Sugihara, Kenichi ; Kitagawa, Yuukou ; Hatake, Kiyohiko ; Gemma, Akihiko ; Yamazaki, Naoya ; Muro, Kei ; Hamaguchi, Tetsuya ; Yoshino, Takayuki ; Yana, Ikuo ; Ueno, Hiroshi ; Ohtsu, Atsushi. / Panitumumab in Japanese patients with unresectable colorectal cancer : a post-marketing surveillance study of 3085 patients. In: Japanese Journal of Clinical Oncology. 2014 ; Vol. 44, No. 3. pp. 214-223.
@article{df0a36e9b7264484a6722c3f851d3fdf,
title = "Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.",
abstract = "Panitumumab was approved in Japan in April 2010 for the treatment of Kirsten rat sarcoma-2 virus oncogene wild-type unresectable and recurrent colorectal cancer. We conducted a post-marketing surveillance study to evaluate the safety and effectiveness of panitumumab. After panitumumab was commercially available in Japan, all patients to be treated with panitumumab were enrolled. Data on baseline characteristics, treatment outcome, and incidence and severity of adverse drug reactions were collected. In total, 3091 patients were registered. In the safety analysis set (n = 3085), panitumumab was administered as monotherapy (40.7{\%}) or combination therapy (59.4{\%}). The median treatment duration was 113 days (range: 1-559 days), and 451 (14.6{\%}) patients received panitumumab for ≥10 months. The overall incidence rate of adverse drug reactions was 84.1{\%}, and the most common adverse drug reaction was skin disorders (78.4{\%}). The incidence rates (all grades) of interstitial lung disease, infusion reaction, electrolyte abnormalities and cardiac disorders were 1.3{\%} (mortality rate: 0.6{\%}), 1.5, 19.3 and 0.2{\%}, respectively. The median survival time of patients treated with panitumumab monotherapy as the third-line, or later, therapy was 10.3 months. This post-marketing survey in clinical practice confirmed the safety and effectiveness of panitumumab. The benefit/risk balance for panitumumab in Japanese patients with unresectable colorectal cancer remains favorable.",
author = "Narikazu Boku and Kenichi Sugihara and Yuukou Kitagawa and Kiyohiko Hatake and Akihiko Gemma and Naoya Yamazaki and Kei Muro and Tetsuya Hamaguchi and Takayuki Yoshino and Ikuo Yana and Hiroshi Ueno and Atsushi Ohtsu",
year = "2014",
doi = "10.1093/jjco/hyt196",
language = "English",
volume = "44",
pages = "214--223",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Panitumumab in Japanese patients with unresectable colorectal cancer

T2 - a post-marketing surveillance study of 3085 patients.

AU - Boku, Narikazu

AU - Sugihara, Kenichi

AU - Kitagawa, Yuukou

AU - Hatake, Kiyohiko

AU - Gemma, Akihiko

AU - Yamazaki, Naoya

AU - Muro, Kei

AU - Hamaguchi, Tetsuya

AU - Yoshino, Takayuki

AU - Yana, Ikuo

AU - Ueno, Hiroshi

AU - Ohtsu, Atsushi

PY - 2014

Y1 - 2014

N2 - Panitumumab was approved in Japan in April 2010 for the treatment of Kirsten rat sarcoma-2 virus oncogene wild-type unresectable and recurrent colorectal cancer. We conducted a post-marketing surveillance study to evaluate the safety and effectiveness of panitumumab. After panitumumab was commercially available in Japan, all patients to be treated with panitumumab were enrolled. Data on baseline characteristics, treatment outcome, and incidence and severity of adverse drug reactions were collected. In total, 3091 patients were registered. In the safety analysis set (n = 3085), panitumumab was administered as monotherapy (40.7%) or combination therapy (59.4%). The median treatment duration was 113 days (range: 1-559 days), and 451 (14.6%) patients received panitumumab for ≥10 months. The overall incidence rate of adverse drug reactions was 84.1%, and the most common adverse drug reaction was skin disorders (78.4%). The incidence rates (all grades) of interstitial lung disease, infusion reaction, electrolyte abnormalities and cardiac disorders were 1.3% (mortality rate: 0.6%), 1.5, 19.3 and 0.2%, respectively. The median survival time of patients treated with panitumumab monotherapy as the third-line, or later, therapy was 10.3 months. This post-marketing survey in clinical practice confirmed the safety and effectiveness of panitumumab. The benefit/risk balance for panitumumab in Japanese patients with unresectable colorectal cancer remains favorable.

AB - Panitumumab was approved in Japan in April 2010 for the treatment of Kirsten rat sarcoma-2 virus oncogene wild-type unresectable and recurrent colorectal cancer. We conducted a post-marketing surveillance study to evaluate the safety and effectiveness of panitumumab. After panitumumab was commercially available in Japan, all patients to be treated with panitumumab were enrolled. Data on baseline characteristics, treatment outcome, and incidence and severity of adverse drug reactions were collected. In total, 3091 patients were registered. In the safety analysis set (n = 3085), panitumumab was administered as monotherapy (40.7%) or combination therapy (59.4%). The median treatment duration was 113 days (range: 1-559 days), and 451 (14.6%) patients received panitumumab for ≥10 months. The overall incidence rate of adverse drug reactions was 84.1%, and the most common adverse drug reaction was skin disorders (78.4%). The incidence rates (all grades) of interstitial lung disease, infusion reaction, electrolyte abnormalities and cardiac disorders were 1.3% (mortality rate: 0.6%), 1.5, 19.3 and 0.2%, respectively. The median survival time of patients treated with panitumumab monotherapy as the third-line, or later, therapy was 10.3 months. This post-marketing survey in clinical practice confirmed the safety and effectiveness of panitumumab. The benefit/risk balance for panitumumab in Japanese patients with unresectable colorectal cancer remains favorable.

UR - http://www.scopus.com/inward/record.url?scp=84899472773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899472773&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt196

DO - 10.1093/jjco/hyt196

M3 - Article

VL - 44

SP - 214

EP - 223

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

ER -